These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23778722)

  • 21. Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial.
    Scholtz AW; Hahn A; Stefflova B; Medzhidieva D; Ryazantsev SV; Paschinin A; Kunelskaya N; Schumacher K; Weisshaar G
    Clin Drug Investig; 2019 Nov; 39(11):1045-1056. PubMed ID: 31571128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of medical treatment for Menière's disease, using a double-blind controlled study.
    Mizukoshi K; Watanabe I; Matsunaga T; Hinoki M; Komatsuzaki A; Takayasu S; Tokita T; Matsuoka I; Matsunaga T; Tanaka T
    Am J Otol; 1988 Sep; 9(5):418-22. PubMed ID: 3202132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Picrotoxin in the treatment of Menière's disease].
    Weikert S; Rotter A; Scherer H; Hölzl M
    Laryngorhinootologie; 2008 Dec; 87(12):862-6. PubMed ID: 18720328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is betahistine effective for Ménière’s disease?
    Rosenbaum A; Winter M
    Medwave; 2017 Oct; 17(8):e7068. PubMed ID: 29099816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.
    Monzani D; Barillari MR; Alicandri Ciufelli M; Aggazzotti Cavazza E; Neri V; Presutti L; Genovese E
    Acta Otorhinolaryngol Ital; 2012 Dec; 32(6):393-403. PubMed ID: 23349559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of transtympanic low-pressure therapy in patients with unilateral Menière's disease unresponsive to betahistine: a randomised, placebo-controlled, double-blinded, clinical trial.
    Gürkov R; Filipe Mingas LB; Rader T; Louza J; Olzowy B; Krause E
    J Laryngol Otol; 2012 Apr; 126(4):356-62. PubMed ID: 22365373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The benefits of betahistine or vestibular rehabilitation (Tetrax biofeedback) on the quality of life and fall risk in patients with Ménière's disease.
    Liu JL; Liu JG; Chen XB; Liu YH
    J Laryngol Otol; 2020 Dec; 134(12):1073-1076. PubMed ID: 33280619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histamine in the treatment of vertigo.
    Fischer AJ
    Acta Otolaryngol Suppl; 1991; 479():24-8. PubMed ID: 2068937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient Perceptions of Effectiveness in Treatments for Menière's Disease: a National Survey in Italy.
    Ward B; Wettstein V; Golding J; Corallo G; Nuti D; Trabalzini F; Mandala M
    J Int Adv Otol; 2019 Apr; 15(1):112-117. PubMed ID: 31058600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hearing function after betahistine therapy in patients with Ménière's disease.
    Seyed Tootoonchi SJ; Ghiasi S; Shadara P; Samani SM; Fouladi DF
    Braz J Otorhinolaryngol; 2016; 82(5):500-6. PubMed ID: 26810620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Betahistine in the treatment of vertigo. History and clinical implications of recent pharmacological researches.
    Mira E
    Acta Otorhinolaryngol Ital; 2001 Jun; 21(3 Suppl 66):1-7. PubMed ID: 11677834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Betahistine in vestibular disorders: current concepts and perspectives].
    Zamergrad MV; Kunelskaya NL; Guseva AL; Amelin AV; Lilenko SV; Samartcev IN; Zaytseva OV; Melnikov OA; Voronov VA; Lyapin AV
    Vestn Otorinolaringol; 2021; 86(2):73-81. PubMed ID: 33929156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Long-term therapy of Ménière's disease. Comparison of the effects of betahistine dihydrochloride and hydrochlorothiazide].
    Petermann W; Mulch G
    Fortschr Med; 1982 Mar; 100(10):431-5. PubMed ID: 7040186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study.
    Pérez-Garrigues H; Kuessner D; Benecke H
    Curr Med Res Opin; 2007 Nov; 23(11):2753-61. PubMed ID: 17910803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of Menière's disease with betahistine (author's transl)].
    Stupp H; Kahl S
    HNO; 1976 Sep; 24(9):320-5. PubMed ID: 965272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Betahistine for Meniere's disease.
    Harcourt J; Cosentino S
    BMJ; 2016 Jan; 352():i46. PubMed ID: 26794224
    [No Abstract]   [Full Text] [Related]  

  • 37. Betahistine or Cinnarizine for treatment of Meniere's disease.
    Djelilovic-Vranic J; Alajbegovic A; Tiric-Campara M; Volic A; Sarajlic Z; Osmanagic E; Todorovic L; Beslagic O
    Med Arch; 2012; 66(6):396-8. PubMed ID: 23409520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Betahistine treatment of Menière's disease (author's transl)].
    Chüden HG
    Laryngol Rhinol Otol (Stuttg); 1978 Nov; 57(11):997-1007. PubMed ID: 723406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of Meniere disease with betahistine dimesilate (Aequamen)--double-blind study versus placebo (crossover)].
    Meyer ED
    Laryngol Rhinol Otol (Stuttg); 1985 May; 64(5):269-72. PubMed ID: 3894841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series.
    Lezius F; Adrion C; Mansmann U; Jahn K; Strupp M
    Eur Arch Otorhinolaryngol; 2011 Aug; 268(8):1237-1240. PubMed ID: 21626121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.